Immunomonitoring of stable renal transplantation patients receiving triple immunosuppressive therapy - Immunomonitoring of stable renal transplantation patients

Centre for Human Drug Research0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年6月11日

试验速览

暂无简介。

•- Signed informed consent prior to any study-mandated procedure
•- Male or female kidney transplantation patients >18 years of age (inclusive)
•- Patients that have undergone a kidney transplantation > 2 years before study
•- Patients on maintenance immunosuppression with low-dose prednisolone, MMF and
•tacrolimus adjusted to target trough levels.
•- Patients that have the ability to communicate well with the Investigator in
•the Dutch language and willing to comply with the study restrictions

•- The use of any medication other than the patient*s standard treatment within
•less than 5 half-lives prior to study participation, if the investigator judges
•that it may interfere with the study objectives;
•- The use of immunosuppressive or immunomodulatory medication, other than the
•patient*s standard treatment, within 3 months before study participation, if
•the investigator judges that it may interfere with the study objectives;
•- Any known factor, condition, or disease that might interfere with study
•conduct or interpretation of the results, in the opinion of the investigator.
•- Unwillingness or inability to comply with the study protocol for any other

发起方